Linked Life Data

2434868

Source:http://linkedlifedata.com/resource/pubmed/id/2434868

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1987-4-7
pubmed:abstractText
Hepatocellular cancer, due to its size and location, allows tumor volume reconstruction and dosimetric determination when radiolabeled antibodies are administered during therapy. Factors identified in the treatment of this cancer may have general applicability for the radiolabeled antibody treatment of other malignancies. These factors include antibody preparations, labeling levels, and toxic effects. New findings regarding tumor volume saturation and altered tumor vascular permeability following radiation have important implications and should be investigated in other tumor systems. Another important development is the use of a new radiolabel, 90Y, in cyclic therapy, which is the sequential use of antibodies derived from different species. This therapy has increased the radiation dose to the tumor.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0893-2751
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7-41
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Hepatoma: model for radiolabeled antibody in cancer treatment.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't